SUMMARY Serum levels of progesterone, cortisol and phenytoin as well as the excretion of 17-OHCS were determined in 45 male epileptics before and during 24 months of the therapy. A significant decrease of the hormones was found in untreated patients. Phenytoin administration caused further decrease of cortisol and its metabolite 17-OHCS levels and a compensation of progesterone serum concentration.
Investigations of the activity of hypothalamicpituitary-adrenal cortex axis have been mainly concerned in aspects to the influence of anticonvulsants on adrenal cortex function.'-`After long-term treatment patients have shown a decrease of serum and urinary levels of glicocorticosteroid hormones as well as a diminished adrenal cortex response to metapirone and dexamethasone. l 3 5 -7 9 -11 The aim of this study was to determine whether the disease itself may have an influence on adrenal cortex function apart from the effect of therapy, with one frequently used antiepileptic drug, phenytoin. Adrenocortical hormones were determined before and during a 2 year period of anticonvulsant therapy.
Material and method
Forty five male patients, aged 20-49 years (mean age 32 4 + 8 6) admitted for the first time to the Centre for Epilepsy at Zabrze and never before treated for epilepsy, were studied. Mean age of onset was 27 4 + 11-3 years. In 26 patients the period between the first and the next seizure, after which the anticonvulsant therapy was introduced ranged from a few months to 1 year. In 14 other males the period was longer (about 2-4 years), and five cases had initial seizures in childhood with long-term remission without treatment.
In 24 patients the illness could be classified as primary generalised epilepsy. In the remaining 21 cases with known aetiological factors, partial or secondary generalised seizures and focal EEG changes, epilepsy was classified as secondary. Most patients had tonic-clonic seizures; in nine cases temporal lobe seizures were observed, and in two of them together with tonic-clonic fits. During 2 years of observation 19 patients had rare seizures, about one per year (mild epilepsy), and in the remaining 24 patients the incidence of tonic-clonic as well as temporal lobe seizures ranged from one to several in a month (severe epilepsy). In all the patients phenytoin was given in daily doses of 200-300 mg (mean 273-3 + 128-0mg) per day.
Hormone determinations were performed before treatment and then every third month during 2 years of phenytoin therapy (nine inter-ictal determinations in each patient Progesterone serum concentration Before treatment there were already more patients Adrenal cortex hormones in male epileptic patients before and during a 2-year phenytoin treatment 4-29 ± 1-43 [16] 44741 + 135-94 [16] 6-78 + 2-78t [15] 23-45 + 10-22 [18] months 18
4-53 ± 2.16 [16] 449-49 ± 165-69 [16] 6-37 ± 2-53$ [15] 21-65 ± 10-99 [16] 21 4-36 + 1-44 [14] 454-80 ± 213-54 [14] 604 + 2-82$ [14] 4-36 + 1-23 [13] 474 47 + 159-29 [13] 6-38 + 2-99$ [13] fig 2) . After months 3 and 6 of phenytoin therapy cortisol serum levels further decreased (p < 0-01). Therapy continuation caused a certain increase in hormone levels 
J7-OHCS urinary excretion
The results showing lower urinary excretion of cortisol metabolite were found more frequently in untreated patients in control males (fig 1) . Mean urinary excretion of 17-OHCS, significantly lower before therapy (p < 0-01) further decreased during drug administration (p < 0-01) in relation to control values (table 1, fig 2) . In 33% of untreated patients abnormal results were found, and during therapy this percentage increased to 54% (fig 3) .
Serum phenytoin levels
No correlation between the results of hormone determinations and serum phenytoin levels was seen (table 1). The lowest drug level found in the 3rd month of treatment could be associated with irregular drug usage by the patients. [ 7] 502-00 + 197-72 [ 7] 5-89 + 3 19 [ 7] Number of patients in brackets.
